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Aims The aims of this study were to determine whether chronic oestrogen withdrawal inﬂuences the
development of ischaemic preconditioning (IPC) in female hearts, to investigate the mechanism
whereby IPC is impaired, and to assess whether direct activation of protein kinase C (PKC) can mimic
IPC in female hearts with chronic oestrogen depletion.
Methods and results We performed Sham-operation (Sham) or bilateral ovariectomy on 16-week-old
Sprague–Dawley female rats. Ovariectomized rats were randomized to subcutaneous implantation of
17b-estradiol (OxE) or placebo (OxP) pellets. Four weeks later, isolated, perfused hearts were subjected
to 30 min of ischaemia followed by 120 min of reperfusion with or without three cycles of 5 min ischae-
mia/5 min reperfusion. The cardioprotective effect of IPC was completely lost in the OxP group.
Western immunoblots revealed that in the OxP group, IPC failed to translocate PKC1 to the membranous
fraction and that phosphorylation of PKC1 (Ser
729) and phosphoinositide-dependent kinase (PDK)
1 (Ser
241) was impaired. Oestrogen replacement restored the IPC effect, the translocation and
phosphorylation of PKC1, and the phosphorylation of PDK1. In the OxP group, pre-treatment with a
PKC1 selective activator peptide (C–1RACK) mimicked the IPC effect. Pre-treatment with a
phosphatidylinositol-3 kinase inhibitor before IPC abrogated the translocation and phosphorylation of
PKC1 in the Sham group.
Conclusions The cardioprotective effect of IPC is lost in female hearts with chronic oestrogen withdra-
wal and this is due, at least in part, to impaired translocation and phosphorylation of PKC1. Selective
activation of PKC1-mediated signalling can fully restore the IPC effect in a manner analogous to oestro-
gen replacement.
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1. Introduction
In most industrialized nations, coronary heart disease (CHD)
is the leading cause of mortality in adult women. As in
males, the incidence of CHD in females increases with
age,
1 but it is signiﬁcantly lower than that in males until
approximately 70 years of age. Since the incidence of CHD
in females changes dramatically with the menopausal
status,
1 ovarian hormones are believed to protect female
hearts from arteriosclerosis and CHD.
Some epidemiological studies have found that in-hospital
mortality was higher in female patients with acute coronary
syndrome (ACS) when compared with male patients.
2 A
higher age at onset of ACS in female patients may contribute
to higher in-hospital mortality. However, whether mortality
after myocardial infarction is higher in females than in
males remains controversial.
Clinical investigations of the effect of hormone replace-
ment therapy (HRT), such as the Women’s Health Initiative
and the Heart and Oestrogen-Progestin Replacement Study
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3,4 have failed to demonstrate the usefulness of HRT in
preventing the development of CHD and in reducing the
mortality in post-menopausal patients with CHD. Collec-
tively, these clinical trials indicate that HRT should not be
used for the purpose of protecting the cardiovascular
system.
5 At least in part, the failure of these trials reﬂects
the fact that our understanding of the cardiovascular
effects of menopause and HRT is still limited.
The most powerful cardioprotective phenomenon identi-
ﬁed to date is ischaemic preconditioning (IPC), an innate
response that renders the heart relatively resistant to
ischaemia (I)/reperfusion (R) injury.
6,7 Although the effect
of chronic oestrogen deﬁciency on myocardial I/R injury
(including myocardial infarction) has been actively investi-
gated during the last decade,
8–12 little is known regarding
whether chronic oestrogen deﬁciency affects the develop-
ment of IPC. Accordingly, the aim of this study was to deter-
mine the inﬂuence of chronic oestrogen withdrawal on the
development of IPC in female hearts and to investigate
the mechanism(s) whereby the development of IPC is
impaired in this setting. To accomplish these goals, we eval-
uated whether oestrogen replacement can restore the IPC
effect in ovariectomized female rats. In addition, we inves-
tigated whether direct activation of protein kinase C (PKC)
(which triggers the cardioprotective effect of IPC) can
mimic the IPC effect in the absence of oestrogen
replacement.
2. Methods
All procedures in the present study conformed to the principles out-
lined in the Guide for the Care and Use of Laboratory Animals pub-
lished by the USA National Institutes of Health (NIH Publication No.
85-23, revised 1996).
A total of 130 female Sprague–Dawley (SD) rats (16-week-old)
were randomly divided into two groups. Sham-operation (Sham) or
bilateral ovariectomy was performed as described previously.
10–12
Then, ovariectomized rats were randomized to receive either sub-
cutaneous implantation of a 17b-estradiol pellet (60-day release
pellet containing 500 mg, Innovative Research of America, Sarasota,
FL, USA) (OxE group) or a placebo pellet (OxP group).
8,10,11 Success-
ful ovariectomy was conﬁrmed by measurements of serum
17b-estradiol levels and visible atrophy of the uterus when rats
were sacriﬁced.
2.1 Langendorff perfusion of the hearts
Four weeks after the operation, the hearts were quickly excised
under anaesthesia and perfused with modiﬁed Krebs–Henseleit
buffer according to the Langendorff procedure. A plastic catheter
with a latex balloon was inserted into the left ventricle (LV)
through the left atrium, and the LV end-diastolic pressure was
adjusted to 10 mmHg by ﬁlling the balloon with water, as described
previously.
13,14 The hearts were paced at 5 Hz while the LV pressure
was measured and pacing was turned off, and the balloon was
deﬂated during global ischaemia and reperfusion.
A total of 16 rats from each group were assigned to two sub-
groups: IPC(þ) and IPC(2). After a 10 min initial wash-out perfusion
in a non-recirculating mode, the isolated rat hearts were perfused
with Krebs–Heinseleit buffer in a recirculating mode. In the
IPC(2) group, after initial recirculating perfusion for 40 min, the
hearts were subjected to 30 min of global ischaemia, followed by
120 min of reperfusion. In the IPC(þ) group, after 10 min of initial
perfusion, IPC was induced by three cycles of 5 min ischaemia/
5 min reperfusion, followed by 30 min of global ischaemia/120 min
reperfusion. Infarct size (% of LV) was quantitated as described
previously.
15 The perfusate was collected during reperfusion, and
total lactate dehydrogenase (LDH) and creatine kinase (CK) activity
released into the perfusate was measured by standard enzymatic
methods and expressed as IU/g wet weight of the ventricle.
13,14
2.2 Measurement of serum parameters
Serum fasting glucose, total cholesterol, high-density lipoprotein
(HDL)-cholesterol, triglycerides, and free fatty acid (FFA) levels
were measured by standard enzymatic methods. Serum b-estradiol
levels were measured by using commercially available ELISA kits.
2.3 Tissue sample preparation
Before the induction of sustained ischaemia, ﬁve hearts from each
group were harvested quickly for western immunoblotting and
measurement of PKC activity. For western immunoblotting of PKCd
and 1, cytosolic, nuclear, and membranous fractions were prepared
as described previously.
16 For measurement of PKC activity and for
western immunoblotting of phosphorylated PKC1 and phosphory-
lated phosphoinositide-dependent kinase 1 (PDK1), cytosolic and
membranous fractions were prepared as described previously.
15,17
2.4 Measurement of protein kinase C activity
Total PKC activity in the cytosolic and membranous fractions was
measured by using a PKC enzyme assay kit (Amersham Bioscience,
Buckinghamshire, UK) and [g-
32P] ATP, according to the manufac-
turer’s instructions.
2.5 Western immunoblotting
Standard sodium dodecyl sulphate–polyacrylamide gel electrophor-
esis western immunoblotting techniques were used to assess the
protein levels of PKCd, PKC1, PDK1, the phosphorylated form of
PKC1, and the phosphorylated form of PDK1, as described pre-
viously.
13,15,17 Initially, speciﬁc antibodies recognizing the phos-
phorylated form of PKC1 or PDK1 were used; the membranes were
then stripped and reprobed with standard PKC1 or PDK1 antibodies
recognizing both phosphorylated and non-phosphorylated forms in
order to normalize the protein levels of the phosphorylated form.
The total protein contents of PKCd, PKC1, and PDK1 were expressed
as a percentage of the corresponding value in the Sham IPC(2)
group. Polyclonal antibodies against PKCd, PKC1, and phosphory-
lated PKC1 at the Ser
729 residue (p-Ser
729 PKC1) were purchased
from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA) and poly-
clonal antibodies against PDK1 and phosphorylated PDK1 at the
Ser
241 residue (p-Ser
241 PDK1) from Cell Signalling Technology, Inc.
(Beverly, MA, USA).
2.6 Effect of protein kinase C activators
Forty-two rats from the Sham and the Ox groups were assigned to
three subgroups. After initial perfusion in a recirculating mode for
10 min, the perfusate was switched to the modiﬁed K–H buffer con-
taining one of the following drugs: 1,2-dioctanoly sn-glycerol (DOG;
Sigma Chemical, St Louis, MO, USA) (10 mM), c–1RACK (KAE1-1; Kai
Pharmaceuticals, South San Francisco, CA, USA) (200 nM), or C1
(control peptide; Kai Pharmaceuticals) (200 nM) (n ¼ 7, each).
After 10 min, the perfusate was switched back to the normal
buffer, and then the hearts were perfused in a non-recirculating
mode for 10 min to wash out each drug. All the hearts were then
subjected to 30 min of global ischaemia/120 min of reperfusion.
The dose of DOG used in this study has previously been shown to
attenuate myocardial I/R injury without changes in the heart rate
or LV pressure in isolated perfused male rat hearts.
16,18 DOG was dis-
solved in dimethyl sulfoxide (DMSO) and the ﬁnal concentration of
DMSO was 0.02%. Inagaki et al.
19 have reported that pre-treatment
with 500 nM of C–1RACK attenuated myocardial I/R injury without
affecting the heart rate or LV pressure in isolated perfused male
K. Shinmura et al. 388rat hearts. However, C–1RACK at a concentration of 500 nM had a
positive inotropic effect in our model (data not shown); therefore,
we used 200 nM C–1RACK. Immediately before use, C–1RACK and
C1 were directly dissolved in the Krebs–Henseleit buffer.
2.7 Effect of the phosphatidylinositol-3
(PI3)-kinase inhibitor
Five hearts in the Sham and OxP groups underwent initial perfusion
in a recirculating mode for 10 min, following which the perfusate
was switched to the modiﬁed Krebs–Henseleit buffer containing
wortmannin (Wako Pure Chemical, Osaka, Japan) (100 nM).
18
After 10 min, the hearts were subjected to the IPC protocol
(3   5 min ischaemia/5 min reperfusion) and immediately har-
vested for western immunoblotting of PKC1. Wortmannin was dis-
solved in DMSO and the ﬁnal concentration of DMSO was 0.02%.
2.8 Statistical analyses
Data are reported as the mean+SEM. For intragroup comparisons,
haemodynamic variables were analysed by a two-way analysis of
variance (ANOVA) (time and group), followed by a Scheffe’s post
hoc test. For intergroup comparisons, data were analysed by a
one-way ANOVA, followed by a Scheffe’s post hoc test. The
P-value of less than 0.05 was deﬁned as statistically signiﬁcant.
Statistical analyses were performed using Stat-View 5.0 software
(SAS Institute, Cary, NC, USA) for Windows.
3. Results
Body weight and total ventricular weight increased signiﬁ-
cantly in the OxP group. However, the ratio of ventricular
weight to body weight in the OxP group was lower than
that in the Sham group (Table 1). Oestrogen replacement
restored these values to the levels seen in the Sham
group. Serum estradiol levels decreased signiﬁcantly in the
OxP group, but did not become zero (Table 1), because
the adrenal glands also produce small amount of sex hor-
mones. The average levels of serum estradiol in the OxE
group were 2.5-fold higher than those in the Sham group
but were still in the physiological range. Serum total choles-
terol levels were higher and serum FFA levels were lower in
the OxP group compared with the Sham group (Table 1).
Oestrogen replacement restored serum FFA levels and
increased serum HDL-cholesterol levels.
Left ventricular function at baseline did not differ among
the three groups (Table 2). In the absence of IPC, infarct size
did not differ among the three groups, although infarct size
in the OxE group tended to be smaller than that in the OxP
group (0.1 , P , 0.05) (Figure 1A). Ischaemic pre-
conditioning signiﬁcantly reduced infarct size and total CK
and LDH release into the perfusate during reperfusion in
the Sham and OxE groups (Figure 1A, B and C). However,
in the OxP group, IPC failed to reduce infarct size and
total CK and LDH release.
Pre-treatment with DOG, C–1RACK, or C1 did not affect
the LV function in any group (Table 2). Pre-treatment with
C–1RACK signiﬁcantly reduced infarct size in both groups
(Figure 1A). In contrast, a favourable effect of DOG on
infarct size was observed only in the Sham group. Pre-
treatment with C1 did not affect the infarct size in either
group. In the Sham group, both DOG and C–1RACK attenu-
ated total CK and LDH release into the perfusate during
reperfusion, whereas C1 had no effect (Figure 1B and C).
In the OxP group, however, total CK and LDH release into
the perfusate was reduced by C–1RACK, not by the DOG.
There was no difference in the total PKC activity among
groups (Figure 2A). In the absence of IPC, the ratio of PKC
activity in the membranous fraction to total activity was
lower in the OxP group compared with the Sham group.
Ischaemic preconditioning increased the ratio of PKC
activity in the membranous fraction to the total PKC activity
in all groups, and there was no difference among groups
(Figure 2B). The protein levels and the distribution of
PKCd and PKC1 did not differ among the three groups
without IPC (data not shown). Ischaemic preconditioning
translocated PKCd to the membranous fraction in all
groups (Figure 3A). Ischaemic preconditioning translocated
PKC1 to the membranous fraction in the Sham and OxE
groups, but not in the OxP group (Figure 3B).
Ischaemic preconditioning increased p-Ser
729 PKC1 in the
cytosolic fraction in all groups, but the increase in the OxP
group was signiﬁcantly less than that in the Sham group
(Figure 4A). In contrast, the levels of p-Ser
729 PKC1 in the
membranous fraction did not differ between the pre-
conditioned and non-preconditioned rats in each group. In
the absence of IPC, the protein levels and the distribution
of PDK1 did not differ among the three groups (data not
Table 1 Body weight, total ventricular weight, and serum parameters
Sham OxP OxE
(n ¼ 16) (n ¼ 16) (n ¼ 16)
Body weight (g) 305+1 364+1* 294+3**
Total ventricular weight (g) 1.23+0.01 1.36+0.01* 1.17+0.03**
Total ventricular weight/body weight (%) 0.41+0.01 0.37+0.01* 0.40+0.03**
Serum parameters (n ¼ 8) (n ¼ 8) (n ¼ 8)
Fasting blood sugar (mg/dL) 143+15 147+20 138+16
Total cholesterol (mg/dL) 89+7 102+5* 98+7
HDL-cholesterol (mg/dL) 26+22 8 +13 0 +2*
Triglycerides (mg/dL) 10.3+0.6 9.2+0.9 9.4+1.2
Free fatty acids (mEq/L) 604+52 518+61* 625+56**
(n ¼ 16) (n ¼ 16) (n ¼ 16)
Serum estradiol levels (pg/mL) 25.4+1.4 6.0+0.2* 63.0+4.0*
,**
Sham, Sham-operation group; OxP, bilateral ovariectomy plus placebo pellet implantation group; OxE, bilateral ovariectomy plus 17b-estradiol pellet
implantation group; HDL, high-density lipoprotein; *P , 0.05 vs. the Sham group, **P , 0.05 vs. the OxP group.
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241 PDK1
to total PDK1 was higher in the OxE group when
compared with the Sham group (Figure 4B). Ischaemic pre-
conditioning increased p-Se
241 PDK1 in the cytosolic fraction
in the Sham and OxE groups, but not in the OxP group.
In the Sham group, treatment with wortmannin prior to
IPC abrogated PKC1 translocation to the membranous frac-
tion following IPC (Figure 5A). Treatment with wortmannin
prior to IPC also abrogated the increase in p-Ser
729 PKC1 in
the cytosolic fraction following IPC in the Sham group
(Figure 5B). No further changes in the distribution or phos-
phorylation of PKC1 were observed in the OxP group
treated with wortmannin (data not shown).
4. Discussion
This study provides several major new ﬁndings. Our data
demonstrate that, in female hearts with chronic oestrogen
withdrawal, (i) the cardioprotective effects of IPC are abro-
gated; (ii) IPC fails to translocate PKC1 to the membranous
fraction; (iii) the IPC-induced phosphorylation of PKC1 at
the Ser
729 residue is impaired; (iv) oestrogen replacement
restores the IPC effect, as well as the translocation and phos-
phorylation of PKC1; and (v) pre-treatment with a selective
activator of PKC1-mediated signalling, but not with a non-
selective PKC activator, also rescues the phenotype and
successfully mimics the salubrious effects of IPC. In addition,
our data demonstrate that in the female heart,
PI3-kinase-mediated signalling is located upstream of the
activation of PKC1 during the development of IPC. Our ﬁnd-
ings imply that the mechanism responsible for the loss of
IPC in ovariectomized rats is at the level of PKC1 or proximal
to it, and that the downstream signalling pathways involved
in the IPC are intact and can be effectively mobilized.
Although in the present study, chronic oestrogen withdra-
wal did not affect myocardial I/R injury in the
non-preconditioned state; the results of previous studies
of this issue have been controversial.
8–12 Likewise, the
data regarding whether chronic oestrogen depletion inter-
feres with the development of IPC have not been entirely
consistent.
20–22 The apparent discrepancy in the previous
reports might be due, at least in part, to different exper-
imental models (in vivo vs. ex vivo), different I/R or IPC pro-
tocols, different parameters used to assess myocardial
damage, and, possibly, species differences. Song et al.
22
demonstrated that chronic oestrogen withdrawal by ovari-
ectomy increased infarct size and exacerbated the recovery
of the LV function after I/R in isolated female mouse hearts.
They further indicated that gonadectomy impaired the
development of IPC in both male and female mice. Peng
et al. reported that ovariectomy did not affect the recovery
of the LV function after I/R in isolated perfused rat hearts;
however, the effect of IPC on the recovery of the LV function
was less in ovariectomized rats than in Sham-operated
rats.
20 Sbarouni et al.
21 demonstrated that in an in vivo
rabbit model, ovariectomy did not affect infarct size
either in the absence or in the presence of IPC. However,
ovariectomized rabbits showed considerable variability in
infarct size and the effect of IPC on infarct size tended to
be attenuated when compared with intact rabbits (infarct
size: intact rabbits, 0.144+0.021 cm
3 vs. ovariectomized
rabbits, 0.249+0.028 cm
3; n ¼ 6 each), although the
difference was not statistically signiﬁcant.
21 Together,
these reports support the concept that the IPC effect is, in
some way, impaired in female hearts with chronic oestrogen
withdrawal; however, they do not provide mechanistic
insights into how chronic oestrogen withdrawal impairs the
IPC effect.
Table 2 Cardiac parameters in each group
Parameter Baseline After treatment
LVSP
(mmHg)
LVEDP
(mmHg)
LVDP
(mmHg)
þdP/dt 2dP/dt LVSP
(mmHg)
LVEDP
(mmHg)
LVDP
(mmHg)
Sham
IPC(2)( n ¼ 8) 91+7 10.1+0.1 80+8 2480+130 1510+90
IPC(þ)( n ¼ 8) 86+3 10.1+0.3 75+3 2470+110 1490+80
Sham IPC(2)
þDOG (n ¼ 7) 90+7 10.3+0.3 80+7 2390+120 1450+80 85+6 10.5+0.3 74+6 (93+4)
þC1 (n ¼ 7) 91+8 10.5+0.3 81+8 2480+140 1500+90 95+5 10.5+0.4 84+5 (104+4)
þc–1RACK
(n ¼ 7)
89+5 10.3+0.3 79+5 2420+110 1480+70 93+5 10.6+0.6 82+5 (105+5)
OxP
IPC(2)( n ¼ 8) 86+6 10.3+0.3 76+6 2350+120 1440+80
IPC(þ)( n ¼ 8) 87+3 10.5+0.1 77+3 2410+100 1480+70
OxP IPC(2)
þDOG (n ¼ 7) 85+4 10.3+0.4 75+4 2390+120 1450+90 82+4 10.6+0.4 71+4 (96+3)
þC1 (n ¼ 7) 86+4 10.5+0.2 75+4 2420+110 1480+80 86+5 10.6+0.2 75+5 (100+4)
þc–1RACK
(n ¼ 7)
90+3 10.5+0.3 79+3 2380+90 1440+70 91+5 10.5+0.3 81+5 (103+8)
OxE
IPC(2)( n ¼ 8) 92+7 9.9+0.1 82+6 2510+110 1610+90
IPC(þ)( n ¼ 8) 94+6 10.0+0.3 84+7 2530+100 1620+90
LVSP, left ventricular systolic pressure; LVEDP, left ventricular end-diastolic pressure; LVDP, left ventricular developed pressure; þdP/dt, peak positive
dP/dt; 2dP/dt, peak negative dP/dt; data in parentheses, percentage change of corresponding value at baseline.
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implanted with 17b-estradiol pellets tended to be smaller
than that in ovariectomized rats implanted with placebo
pellets (Figure 1). This ﬁnding may support the previous
reports that exogenous 17b-estradiol administration, in
itself, exerts the cardioprotective effect.
8,10 However, the
evidence that chronic oestrogen replacement interferes
with myocardial ischaemic/reperfusion injury has not been
entirely consistent. As expected, oestrogen replacement
successfully restored the IPC effect in the ovariectomized
rat heart (Figure 1).
Protein kinase C plays a key role in the IPC signalling
cascade in cardiomyocytes.
6,7,23,24 Among the various iso-
forms of PKC, PKCa, d, and 1 have been reported to be
translocated to the membranous fraction by IPC in young
male rat hearts.
25 We previously demonstrated that the
IPC effect is lost in middle-aged male rat hearts.
14 Addition-
ally, Tani et al.
16 have demonstrated that IPC failed to trans-
locate both PKCd and 1 to the membranous fraction in
middle-aged male rat hearts. Accordingly, we ﬁrst investi-
gated the intracellular distribution of PKCd and 1 before
and after IPC. In contrast to middle-aged male hearts, IPC
translocated PKCd to the membranous fraction but failed
to translocate PKC1 to the membranous fraction in female
hearts with chronic oestrogen withdrawal.
We do not have direct evidence that, in the pre-
conditioned myocardium, PKC and PDK1 translocated
instead of pre-existing PKC and PDK1 being degraded in
one location and synthesized and accumulated in another
location. However, the rapidity of the changes in the subcel-
lular distribution of PKC and PDK1 after IPC (observed within
30 min) makes it unlikely that they reﬂected de novo syn-
thesis of those proteins. Mounting evidence also supports
the concept that PKC and other proteins translocate in pre-
conditioned myocardium.
7,17,23 Thus, the most plausible
interpretation of our observations is that a relatively small
amount of PKC and PDK1 translocate after IPC, but this
small change is essential for the development of the IPC
effect.
Several possibilities might explain the impairment in PKC1
translocation in the OxP group. We examined the phosphory-
lated state of PKC1 before and after IPC because recent
investigations demonstrated that phosphorylation of the
three residues located in the kinase domain is essential for
activation and translocation of novel PKC isozymes in
various cell types.
26–29 The phosphorylation of the Thr
566
residue located in the activation loop leads to the autopho-
sphorylation of the Thr
710 residue at the turn motif.
26,28 The
Ser
729 residue in the hydrophobic motif at the C-terminus
may then be autophosphorylated
26,28 or it may be phos-
phorylated by an autologous kinase controlled by mTOR,
30
thus making PKC1 ready for translocation. Accordingly, the
impaired p-Ser
729 PKC1 observed in our study (Figure 4A)
suggests a decrease in the capacity of PKC1 for translocation
to the membranous fraction. In fact, Xu et al.
31 have
demonstrated that phosphorylation of the Ser
729 residue is
required for the determination of the intracellular localiz-
ation of PKC1 and for its interaction with target proteins
in 3T3 ﬁbroblasts.
In cardiomyocytes, the exact mechanism whereby the
three residues in the kinase domain of PKC1 are phosphory-
lated remains unsolved. Rybin et al.
32 reported that in
neonatal cardiomyocytes, the Ser
729 residue of PKC1 is phos-
phorylated by PKCd and, in turn, the Thr
505 residue of PKCd
is phosphorylated by PKC1. Whether this concept can be
applied to adult female hearts is unclear because of the
differences in the expression levels of novel PKC isoforms
Figure 2 Protein kinase C activity. (A) Total protein kinase C activity. (B)
Percentage of protein kinase C activity in the membranous or cytosolic frac-
tion as a fraction of the total protein kinase C activity. Data are represented
as the mean+SEM. *P , 0.05 vs. the corresponding IPC(2) group,
$P , 0.05
vs. the corresponding Sham group.
Figure 1 The effect of ischaemic preconditioning, direct protein kinase C
activation by 1,2-dioctanoly sn-glycerol, c–1RACK (KAE1-1), or control
peptide (C1) on infarct size in each group. (A) Infarct size. (B) Total lactate
dehydrogenase activity released into the perfusate during reperfusion. (C)
Total creatine kinase activity released into the perfusate during reperfusion.
Data are represented as the mean+SEM. *P , 0.05 vs. the corresponding
IPC(2) group,
þP , 0.05 vs. the corresponding þC1 group.
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33 Although
most data have been obtained in 3T3 ﬁbroblasts rather
than in cardiomyocytes, increasing evidence demonstrates
that PDK1 is the upstream kinase that directly phosphory-
lates the active loop of PKC1.
27–29 PDK1 is bound to and
activated by lipid metabolites that are produced by
PI3-kinase. PDK1 phosphorylated at the Ser
241 residue (an
Figure 3 Western immunoblotting for protein kinase C d and 1.( A) Densitometric analysis of protein kinase C d in the membranous (MF), cytosolic (CF), and
nuclear fractions (NF). (B) Densitometric analysis of protein kinase C 1 in MF, CF, and NF. The densitometric measurements of protein kinase C are normalized
to the total protein detected and expressed as a percentage of the average values measured in the Sham IPC(2) group. Data are represented as the mean+SEM.
*P , 0.05 vs. the corresponding IPC(2) group,
$P , 0.05 vs. the corresponding Sham group.
Figure 4 Western immunoblotting for phosphorylated forms of protein
kinase C 1 and phosphoinositide-dependent kinase 1. (A) Densitometric analy-
sis of phosphorylated protein kinase C 1 at the Ser
729 residue in the membra-
nous (MF) and the cytosolic fractions (CF). (B) Densitometric analysis of
phosphorylated phosphoinositide-dependent kinase 1 at the Ser
241 residue
in MF and CF. The densitometric measurements of phosphorylated proteins
are normalized to the total protein detected and expressed as a percentage
of the average values measured in the Sham IPC(2) group. Data are rep-
resented as the mean+SEM. *P , 0.05 vs. the corresponding IPC(2) group,
$P , 0.05 vs. the corresponding Sham group.
Figure 5 Effect of the PI3-kinase inhibitor (wortmannin) on the transloca-
tion and the phosphorylation of protein kinase C 1 after IPC in the Sham
group. (A) Densitometric analysis of protein kinase C 1 in MF, CF, and NF.
(B) Densitometric analysis of p-Ser
729 protein kinase C 1 in MF and CF. Data
are represented as the mean+SEM. *P , 0.05 vs. the corresponding IPC(2)
group,
$P , 0.05 vs. the corresponding Sham group.
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mediate further signalling pathways.
28,34 Tong et al.
18
demonstrated that IPC induced phosphorylation of Akt/PKB
and translocation of PKC1 and, in male rat hearts, a
PI3-kinase inhibitor blocked these effects of IPC. They also
found that a PI3-kinase inhibitor abrogated the cardiopro-
tective effect of IPC but did not completely eliminate the
effect of direct PKC activation by DOG. They concluded
that in male hearts, IPC activates PI3-kinase upstream of
PKC1. In the present study, IPC failed to translocate the
p-Ser
241 PDK1 to the cytosolic fraction in female hearts
with chronic oestrogen withdrawal (Figure 4B). In addition,
administration of a PI3-kinase inhibitor prior to IPC abro-
gated the translocation of PKC1 to the membranous fraction
and attenuated the p-Ser
729 PKC1 in intact female hearts in
analogy with the effects observed in female hearts with
chronic oestrogen withdrawal (Figure 5). Our ﬁnding that
the effect of non-selective PKC activation by DOG was insuf-
ﬁcient in female hearts with chronic oestrogen withdrawal
(Table 2 and Figure 2) would not contradict the ﬁndings of
Tong et al.,
18 if PI3-kinase-mediated signalling is impaired
in the ovariectomized rat heart. Mounting evidence indi-
cates that activation of oestrogen receptors directly modu-
lates PI3-kinase/PDK/AKt signalling in cardiomyocytes.
35,36
Therefore, it is plausible that chronic oestrogen withdrawal
may cause dysfunction of PKC1 via impaired PI3-kinase/PDK/
Akt signalling. In the absence of IPC, the ratio of p-Se
241
PDK1 to total PDK1 in the cytosolic fractions in the OxE
group was higher than that in the Sham group (Figure 4B),
suggesting that oestrogen replacement affects PI3-kinase/
PDK/Akt signalling. Activation of PI3-kinase/PDK/Akt signal-
ling might be responsible for the attenuation of myocardial
I/R injury in the OxE group without IPC. As expected, oestro-
gen replacement completely restored the translocation and
phosphorylation of PKC1 after IPC in the ovariectomized rat
heart (Figures 3B and 4A).
We did not evaluate the phosphorylated state of PKC1 at
the Thr
566 residue, which is directly phosphorylated by
PDK1,
26,28,29 because a speciﬁc antibody is not available.
Thus, there is still no direct evidence that impaired
PI3-kinase/PDK/Akt signalling in female hearts with
chronic oestrogen depletion contributes to the loss of
PKC1 translocation. The Thr
505 residue located in the acti-
vation loop of PKCd is also phosphorylated by PDK1.
26,28,29
However, in the present study, translocation of PKCd to
the membranous fraction was preserved in female hearts
with chronic oestrogen depletion. Recent investigations
suggest that unlike PKC1, phosphorylation of PKCd appears
to be dispensable.
29 The difference between the activation
mechanisms of PKCd and PKC1 might explain the discrepancy
in the subcellular trafﬁcking of PKC after IPC in the present
study. Further investigations are required to establish the
interaction between PDK1 and PKC1 in cardiomyocytes.
In summary, we have demonstrated that the cardioprotec-
tive effect of IPC is lost in female hearts with chronic oestro-
gen depletion and that this phenomenon is caused, at least
in part, by impaired phosphorylation of PKC1 at the Ser
729
residue and loss of PKC1 translocation following IPC. We
have also demonstrated that not only oestrogen replace-
ment but also selective activation of PKC1-mediated signal-
ling can fully restore a protective phenotype analogous to
that conferred by IPC. The latter ﬁnding indicates that the
cellular defect caused by oestrogen withdrawal is at the
level of PKC1 or proximal to it, and that the distal cardiopro-
tective machinery is intact and can be effectively recruited
by appropriate interventions. Our results suggest that direct
activation of PKC1-mediated signalling is a potential strat-
egy for restoring protection against ischaemia in female
hearts with chronic oestrogen depletion that might be
more efﬁcacious than HRT.
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